Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Co., Ltd., Cholesterol 24-Hydroxylase (CH24H) Inhi bitor “soticlestat (TAK-935)” Receives “The Pharmaceutical Society of Japan Award”

Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company, Cholesterol 24-Hydroxylase (CH24H) Inhibitor “soticlestat (TAK-935)” Receives “The Pharmaceutical Society of Japan Award”
− Soticlestat, created at Takeda Pharmaceutical’s Shonan R&D facility, was recognized for its contribution to the development of drug discovery through original research on drugs with novel chemical structures

Today, our company received the “The Pharmaceutical Society of Japan, Pharmaceutical Chemistry Subcommittee Award” from the Pharmaceutical Society of Japan, Pharmaceutical Chemistry Subcommittee, for research related to the creation of the cholesterol 24-hydroxylase (CH24H) inhibitor “soticlestat (TAK-935)”. I will inform you that I did. The award ceremony was held online today.
[Imaged90178-26-9e393f7e06966ccd894b-0.jpg&s3=90178-26-98b4c38c32620354237b8d6644c8d392-1299x892.jpg
From left to right, Yoshikawa and Miyamoto. From the bottom left, Nishi, Koike, Ando
Soticlestat is a novel designed and created first-in-class compound that selectively inhibits CH24H and may reduce seizure susceptibility and improve seizure control1.20222 In May, Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS), which are designated as intractable diseases of developmental epileptic encephalopathy (DEE), will be approved as an orphan drug by the Minister of Health, Labor and Welfare. obtained the designation of Phase 3 clinical trials for DS and LGS are currently underway. This time, soticlestat was awarded for its contribution to the development of drug discovery through original research on drugs with novel chemical structures. This year’s award is the first in nine years and the sixth for our company.
The Pharmaceutical Society of Japan The Pharmaceutical Chemistry Subcommittee was established in 1990 as the first subcommittee of the Pharmaceutical Society of Japan. Aiming at the creation of original medicines, this is an academic conference on medicinal chemistry as a forum for research presentations, knowledge exchanges, and
collaboration among members and with domestic and foreign related organizations by members engaged in research in related basic and applied fields. We aim to contribute to the development of
pharmaceutical societies and pharmaceutical-related industries by promoting the progress and dissemination of new drug development, enhancing and strengthening the research base for new drug
development. The Medicinal Chemistry Division Award was established in 2000 to honor the outstanding research achievements of researchers involved in drug discovery research.
Tatsuki Koike, principal investigator of soticlestat and director of our neuroscience drug discovery unit, said, “soticlestat is a new drug candidate designed and created at our research center in Shonan, and is currently in the third clinical stage globally. A phase trial is underway.I am very pleased to receive this award, as I am able to contribute to the advancement of drug discovery through the pursuit of innovative science.”
-List of winners-
Representative researcher: Tatsuki Koike (Takeda Pharmaceutical Company Limited) Collaborator: Masato Yoshikawa (Takeda Pharmaceutical Company Limited) Maki Miyamoto (Takeda Pharmaceutical Company Limited)
Toshiya Nishi (former Takeda Pharmaceutical Company Limited) Haruyo Ando (former Takeda Pharmaceutical Company Limited)
-About soticlestat-
Soticlestat is a highly selective, first-in-class oral cholesterol 24-hydroxylase (CH24H) inhibitor that may reduce seizure
susceptibility and improve seizure control. CH24H is primarily expressed in the brain, where it converts cholesterol to
24S-hydroxycholesterol (24HC) and regulates the homeostatic balance of brain cholesterol. 24HC is a positive allosteric modulator of NMDA receptors and modulates glutamatergic signaling associated with epilepsy. Glutamate is one of the major neurotransmitters in the brain and has been shown to be involved in seizure initiation and
development. A recent paper suggests that 24HC is involved in hyperactivation of the glutamate pathway through modulation of NMDA receptors, and that increased CH24H expression prevents glutamate reuptake by astrocytes, leading to neurological disorders such as epileptogenesis and neuroinflammation. Toxicity has been shown to occur2. Suppression of CH24H by soticlestat reduces neuronal 24HC levels and may ameliorate the excitatory/inhibitory balance distortion in the brain.
-About Takeda-
Headquartered in Japan, Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global R&D-oriented company based on its corporate philosophy and the values ​​of patient-centered thinking. is a leading company in biopharmaceuticals. At Takeda, we aim for a future where we continue to create innovative medicines, keeping in mind the promise of “for all patients, for our colleagues, and for the planet that nurtures life.” R&D focuses on four therapeutic areas: oncology (cancer), rare genetic and hematologic diseases, neuroscience (neuropsychiatric disorders), and gastroenterology, as well as plasma-derived therapies and vaccines Focusing. By strengthening its research and development capabilities, promoting partnerships, and building a strong and diverse modality (therapeutic method) pipeline, Takeda will develop innovative drugs and new treatments that enrich people’s lives. We bring you the choices. Takeda is working together with medical professionals in approximately 80 countries and regions to contribute to improving the quality of life of patients.
For more information, please visit https://www.takeda.com/jp/. Details about this release:
https://prtimes.jp/main/html/rd/p/000000026.000090178.html


rehow

Leave a Reply

Your email address will not be published.

%d bloggers like this: